Mar. 24 at 11:43 AM
Citizens reiterated
$ABVX Market Outperform;
$131, and said:::Top-line results from the ongoing Phase 3 ABTECT-UC trial are anticipated in late-2Q26.
$JNJ -
$PTGX TEVA ROIV - RHHBY SYRE ABBV TAK PFE BMY LLY
Citizens added:::We continue to believe in the potential for positive results, supported by the robust responder rate demonstrated in the induction phase, as well as the Phase 2b long-term extension results.
The recently completed (March 18, 2026) safety review conducted by the independent Data Safety Monitoring Board (DSMB), which found no new safety signals, reinforces our confidence in the candidate's clean safety profile.
We view this as especially notable given this most recent DSMB assessment included all randomized patients in the Phase 3 maintenance trial, with nearly 90% of patients having completed the 44-week trial.
